The utility of fluorescence in situ hybridization testing in patients clinically suspected of myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm overlap is limited in the absence of significant morphological dysplasia.
Harpreet VirkSonia RanaAlpeshkumar B KapadiaSreejesh SreedharanunniNabhajit MallikNarender KumarPrashant SharmaShano NaseemMan Updesh Singh SachdevaJasmina AhluwaliaReena DasNeelam VarmaPankaj MalhotraPublished in: International journal of laboratory hematology (2020)